文献速递淋巴瘤

SHMT2抑制破坏伯基特淋巴瘤中TCF3转录生存程序

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
PubMed 文献 · Blood · 2022-01-01

该研究通过全基因组CRISPR-Cas9筛选发现伯基特淋巴瘤(BL)对B细胞受体信号、特定转录调节因子和一碳代谢存在依赖性。聚焦一碳代谢关键酶SHMT2,敲低或药物抑制SHMT2在体内外均产生抗BL效应,机制为降低细胞内甘氨酸和甲酸盐水平,抑制mTOR通路,触发TCF3自噬性降解,进而瓦解TCF3控制的张力性BCR信号。研究还发现甲氨蝶呤等药物与SHMT抑制剂协同,揭示SHMT2作为药物靶点及其与TCF3的机制联系。

要点

  • SHMT2抑制在体内外均抗伯基特淋巴瘤。
  • SHMT2抑制降低甘氨酸和甲酸盐,抑制mTOR,触发TCF3自噬降解。
  • 甲氨蝶呤等药物与SHMT抑制剂协同。

核心结论

  • SHMT2是伯基特淋巴瘤的 validated 药物靶点,抑制SHMT2通过降低甘氨酸和甲酸盐、抑制mTOR、触发TCF3自噬降解而抗肿瘤。

研究设计与样本

  • 使用全基因组CRISPR-Cas9筛选鉴定伯基特淋巴瘤的脆弱性。
  • 聚焦SHMT2,通过敲低或药理化合物抑制进行体外和体内验证。

主要发现

  • SHMT2抑制导致细胞内甘氨酸和甲酸盐水平显著降低。
  • 甘氨酸和甲酸盐降低抑制mTOR通路,触发TCF3自噬性降解。
  • TCF3降解导致张力性BCR信号崩溃,BL细胞存活受损。

关键数值与推荐

  • SHMT2抑制在体外和体内均诱导抗BL效应。
  • 甲氨蝶呤等药物与SHMT抑制剂协同。

临床怎么用

  • SHMT2可作为伯基特淋巴瘤的潜在治疗靶点。
  • SHMT抑制剂与甲氨蝶呤等药物联用可能具有协同价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt lymphoma (BL) is an aggressive lymphoma type that is currently treated by intensive chemoimmunotherapy. Despite the favorable clinical outcome for most patients with BL, chemotherapy-related toxicity and disease relapse remain major clinical challenges, emphasizing the need for innovative therapies. Using genome-scale CRISPR-Cas9 screens, we identified B-cell receptor (BCR) signaling, specific transcriptional regulators, and one-carbon metabolism as vulnerabilities in BL. We focused on serine hydroxymethyltransferase 2 (SHMT2), a key enzyme in one-carbon metabolism. Inhibition of SHMT2 by either knockdown or pharmacological compounds induced anti-BL effects in vitro and in vivo. Mechanistically, SHMT2 inhibition led to a significant reduction of intracellular glycine and formate levels, which inhibited the mTOR pathway and thereby triggered autophagic degradation of the oncogenic transcription factor TCF3. Consequently, this led to a collapse of tonic BCR signaling, which is controlled by TCF3 and is essential for BL cell survival. In terms of clinical translation, we also identified drugs such as methotrexate that synergized with SHMT inhibitors. Overall, our study has uncovered the dependency landscape in BL, identified and validated SHMT2 as a drug target, and revealed a mechanistic link between SHMT2 and the transcriptional master regulator TCF3, opening up new perspectives for innovative therapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wilke AC, Doebele C, Zindel A, et al. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2022. PMID: 34624079. doi:10.1182/blood.2021012081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。